Nine-Valent Human Papillomavirus Vaccine
（HPV 6/11/16/18/31/33/45/52/58
CECOLIN®9 ）
The first domestically developed nine-valent HPV vaccine in China and the second globally, CECOLIN®9 was approved for marketing by the National Medical Products Administration in 2025. This breakthrough ended the long-standing global technological monopoly of imported high-valent HPV vaccines, making China the second country after the United States to independently supply high-valent HPV vaccines.
This vaccine protects against persistent infections and related diseases caused by seven high-risk HPV types (16, 18, 31, 33, 45, 52, and 58) and two low-risk HPV types (6 and 11), including cervical intraepithelial neoplasia, cervical cancer, adenocarcinoma in situ, and genital warts.
Product Advantages
Superior Technology Platform
Our proprietary prokaryotic expression virus-like particle vaccine technology platform ensures high yield, excellent quality, and safety. This will significantly enhance the accessibility of high-quality vaccines and protect the health of more women.
International Standard Quality
Developed in accordance with EU standards, head-to-head clinical studies with imported nine-valent HPV vaccines have shown comparable immunogenicity and safety, with results published in The Lancet Infectious Diseases.
Solid Clinical Data
Large-scale randomized controlled Phase III clinical trials in women aged 18-45 have shown that the nine-valent HPV vaccine maintains the excellent protection of the bivalent HPV vaccine against HPV 16 and 18 infections and lesions. It also provides over 98% protection against persistent infections (over 12 months) of HPV types 31, 33, 45, 52, and 58 not covered by the bivalent vaccine, with a 100% protection rate against cervical persistent infections. The vaccine has demonstrated good safety throughout the clinical study period.
Flexible Vaccination Schedule
Girls aged 9-17 need only two doses, while women aged 18-45 require three doses.
HPV Vaccine Product Series
Bivalent HPV Vaccine
Bivalent human papillomavirus vaccine (HPV 16&18) is used to prevent cervical cancer and precancerous lesions caused by HPV 16 and 18 infections. It took 16 years to develop, with a cumulative investment of nearly 800 million yuan, and has multiple international certifications and honors.
- Aiming at HPV 16/18 types, these two high-risk types of viruses are the main causes of cervical cancer.
- Women aged 9 to 14 only need to receive two doses of vaccination, simplifying the vaccination procedure.
- The protection rate reaches 100%, and the protection rate against persistent infection for 6 months is as high as 97.7%.
- Wide applicable age range: women aged 9 to 45.
9-valent HPV Vaccine
The 9-valent human papillomavirus vaccine, compared with the bivalent vaccine, adds protection against infections of five high-risk types 31, 33, 45, 52 and 58, as well as two low-risk types of HPV 6 and 11, providing a more comprehensive preventive effect against cervical cancer.
- Prevent infections of 9 types of HPV, covering a broader spectrum of virus types.
- At the same time, it prevents condyloma acuminata caused by low-risk HPV 6 and 11.
- It has independent intellectual property rights for 9 types.
- It is supported by the 863 Project of the Ministry of Science and Technology of China.
For more information : wtexport@ystwt.com
Filing Number:(京)网药械信息备字（2025）第 00190 号
|
Copyright©Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
|
|
京公网安备11011402010353号 
Alibaba Cloud provides cloud computing and security services.|
It supports
|
Powered by CloudDream
|
Terms Of Use|
Privacy Statement